Darmstadt, Germany 3/3/09; Boca Raton, FL 3/3/09—AppliChem GmbH and Akron Biotechnology have merged, with Akron Biotech taking over AppliChem’s operations in the Americas on March 2 and adopting the AppliChem name. AppliChem offers biochemicals and reagents. Akron Biotechnology manufactures stem cell culture products. Dr. Claudia Zylvberberg will remain president and CEO of AppliChem.
Nearly half of life science companies plan to focus on “breakthrough products and niche markets” in order to mitigate R&D risk, according to a survey by Deloitte Touche Tohmatsu and the Economist Intelligence Unit. The survey is based on responses from 360 life science industry executives from healthcare services (23% of respondents), pharmaceutical R&D (22%), […]
New York, NY 3/12/09—Enzo Biochem has acquired substantially all of the assets of Assay Designs for $12.2 million in cash. Assay Designs provides kits and reagents for the detection and quantification of small molecules and proteins that are important in inflammation and immunity, oxidative and cellular stress, steroid and hormone biology, cell signaling, and bioenergetics. […]
Increases in National Health Service spending and other government funds for translational research has lead UK institutes to focus on moving medical research into the clinic more quickly. England is facing competition for medical research and clinical trials from the Asia-Pacific region. According to the Centers for Medicines Research, the number of patients enrolled in […]
The Information Technology and Innovation Foundation (ITIF) reports that Singapore, Sweden, Luxembourg, Denmark and South Korea are the most competitive and innovative nations out of the 40 nations/regions examined. The study is based on 16 indicators in six categories: human capital, innovation capacity, entrepreneurship, IT infrastructure, economic policy and economic performance. The US ranks sixth, […]
Jena, Germany 2/19/09 and 2/23/09—Analytik Jena AG has acquired a majority of CyBio AG by increasing its stake in the company from 5.48%, purchased on February 19, to 51.19% purchased on February 20 at the price of €1.10 ($1.41) per share as part of a voluntary offer to Cybio shareholders. The acquisition will add CyBio’s […]
At this year’s Pittcon, IBO sat down with executives from four major analytical instrument providers to discuss current market conditions and strategies. Each executive acknowledged that this was a difficult time for the instrument market. As Dr. Rohit Khanna, vice president of Worldwide Marketing for the Waters Division of Waters Corporation, stated at the company’s […]
Traditionally, the fourth quarter is the strongest quarter for sales of instruments and associated laboratory products due to budget releases. However, 2008 was not like any other year. Following the beginning of the banking crisis in September and the subsequent rapid deterioration of the worldwide economy, demand from major end-markets for analytical instruments, such as […]
Analytical instrument and laboratory product companies are celebrating the passage of US President Barack Obama’s stimulus plan, the American Recovery and Reinvestment Act (ARRA), which was signed into law on February 17. The ARRA provides $600 million directly for laboratory instrument purchases. It is also expected that part of the funding for research grants will […]
Despite the US government’s approval of a stimulus plan and the infusion of additional capital into the financial system, the markets failed to rally in February. The housing market further deteriorated and unemployment claims reached record highs. On February 27, fourth-quarter 2008 US GDP was revised downward to an annualized contraction of 6.2%, the worst […]
Pay Invoice
Latest Blogs
-
Syncell: Advancing Spatial Proteomics
June 30, 2025 3:41 pm
-
SDi Forecasts Growth in Demand for Analytical Instruments 2024–2029
May 29, 2025 1:38 pm
-
NIH Disruptions and Lab Tool Companies: Stocks React
April 30, 2025 1:17 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
